Equity Details
Price & Market Data
Price: $3.05
Daily Change: -$0.135 / 4.42%
Daily Range: $3.05 - $3.30
Market Cap: $233,834,240
Daily Volume: 500,694
Performance Metrics
1 Week: 6.49%
1 Month: 43.23%
3 Months: 64.00%
6 Months: 67.35%
1 Year: 62.38%
YTD: 77.30%
About Nkarta, Inc. (NKTX)
A financial summary of Nkarta, Inc. (NKTX). Price: 3.05, daily change: -$0.135 / 4.42%. Market cap: 233,834,240. Performance from 3-month to 1-year.
Company Details
Employees: 108
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.